Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval

IvelinRadkov

Sanofi (NASDAQ:SNY) and Regeneron Pharmaeuticals (NASDAQ:REGN) Dupixent (dupiliumab), already a blockbuster drug approved for several indications, including asthma and eosinophilic esophagitis, is poised for further gains as it is likely to gain approval for chronic obstructive pulmonary disease.

Dupixent sales could

ApprovalCOPDDupixentgainslargeRegeneronsSanofiSet
Comments (0)
Add Comment